TY - JOUR
T1 - Prostatic irradiation-induced sexual dysfunction
T2 - A review and multidisciplinary guide to management in the radical radiotherapy era (Part II on Urological Management)
AU - Rogers, Marc J.
AU - Ramirez-Fort, Marigdalia K.
AU - Kashanian, James A.
AU - Broster, Seth A.
AU - Matta, Jaime
AU - Mahase, Sean S.
AU - Fort, Digna V.
AU - Niaz, M. Junaid
AU - McClelland, Shearwood
AU - Bander, Neil H.
AU - Fort, Migdalia
AU - Lange, Christopher S.
AU - Schlegel, Peter
AU - Mulhall, John P.
N1 - Publisher Copyright:
© 2020
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Prostate cancer is the most common malignancy in men and the second leading cause of cancer-related death in men. Radiotherapy is a curative option that is administered via external beam radiation, brachytherapy, or in combination. Sexual dysfunction is a common toxicity following radiotherapy, similar to men undergoing radical prostatectomy, but the etiology is different. The pathophysiology of radiation-induced sexual dysfunction is multi-factorial, and the toxicity is a major cause of impaired quality of life among long-term prostate cancer survivors. Management of a patient's sexual function during and after radiotherapy requires multidisciplinary coordination of care between radiation oncology, urology, psychiatry, pharmacy, and dermatology. This review provides a framework for clinicians to better understand prostatic radiotherapy-induced sexual dysfunction diagnosis, evaluation, and a patient-centered approach to toxicity preventive strategies and management.
AB - Prostate cancer is the most common malignancy in men and the second leading cause of cancer-related death in men. Radiotherapy is a curative option that is administered via external beam radiation, brachytherapy, or in combination. Sexual dysfunction is a common toxicity following radiotherapy, similar to men undergoing radical prostatectomy, but the etiology is different. The pathophysiology of radiation-induced sexual dysfunction is multi-factorial, and the toxicity is a major cause of impaired quality of life among long-term prostate cancer survivors. Management of a patient's sexual function during and after radiotherapy requires multidisciplinary coordination of care between radiation oncology, urology, psychiatry, pharmacy, and dermatology. This review provides a framework for clinicians to better understand prostatic radiotherapy-induced sexual dysfunction diagnosis, evaluation, and a patient-centered approach to toxicity preventive strategies and management.
UR - http://www.scopus.com/inward/record.url?scp=85085932571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085932571&partnerID=8YFLogxK
U2 - 10.1016/j.rpor.2020.03.011
DO - 10.1016/j.rpor.2020.03.011
M3 - Review article
C2 - 32549795
AN - SCOPUS:85085932571
SN - 1507-1367
VL - 25
SP - 619
EP - 624
JO - Reports of Practical Oncology and Radiotherapy
JF - Reports of Practical Oncology and Radiotherapy
IS - 4
ER -